Navigation Links
Arena Pharmaceuticals to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 30, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present corporate updates at the following three upcoming investor conferences:

  • Stifel Nicolaus Healthcare Conference
    Presentation: September 6, 2012, at 9:10 a.m. Eastern Time (6:10 a.m. Pacific Time) at the Four Seasons Hotel in Boston, Massachusetts
    Presenting: Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer 
  • NewsMakers in the Biotech Industry
    Presentation: September 7, 2012, at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Time) at the Millennium Broadway Hotel in New York, New York
    Presenting: Craig M. Audet, Senior Vice President, Operations and Head of Global Regulatory Affairs
  • Bank of America Merrill Lynch Global Healthcare Conference
    Presentation: September 12, 2012, at 8:55 a.m. British Summer Time (12:55 a.m. Pacific Time) at the Bank of America Merrill Lynch Financial Centre in London, England
    Presenting: Dominic P. Behan, Ph.D., Executive Vice President and Chief Scientific Officer 
  • Arena's presentations at these conferences will be webcast live. Each of the audio webcasts will be available under the investor relations section of Arena's website at, and will be archived there for 30 days following the presentation. Please connect to Arena's website several minutes prior to the start of each webcast to ensure adequate time for any software download that may be necessary. 

    Arena also announced today that it is scheduled to participate in panel presentations at Citi's 7th Annual Biotech Day on September 5, 2012, at the Mandarin Oriental Hotel in Boston, Massachusetts and at the Rodman and Renshaw Global Investment Conference on September 10, 2012, at The Waldorf Astoria Hotel in New York, New York. These panel presentations will not be webcast.About Arena Pharmaceuticals
    Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information about Arena, please visit

    Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc.

    Forward-Looking Statements
    Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's efforts, focus, goals, strategy, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the pace of market acceptance; cash and revenues generated from lorcaserin, including the timing and impact of competition; the timing and outcome of regulatory review is uncertain; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; the entry into, modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review, approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

     Contact: Arena Pharmaceuticals, Inc.

    Media Contact: Russo PartnersCindy McGee, Vice President,

    David Schull, PresidentInvestor Relations & Alliance Management

    858.717.2310858.453.7200, ext. 1479 

    SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
    2. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
    3. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
    4. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
    5. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
    6. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
    7. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
    8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
    9. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
    10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
    11. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
    Post Your Comments:
    (Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
    (Date:11/25/2015)... , Nov. 25, 2015  The American Academy ... Gynecologists (ACOG), and the March of Dimes cheered ... Protecting Our Infants Act of 2015 (S.799), ... of newborns born exposed to drugs, such as ... bill,s introduction, all three organizations have worked together ...
    (Date:11/25/2015)... 25, 2015  Henry Schein, Inc., the world,s largest ... dental, medical and animal health practitioners, will unveil at ... Henry Schein ConnectDental® Pavilion , which brings together for ... solutions designed to help any practice or laboratory enter ... for a schedule of experts appearing at the Pavilion. ...
    Breaking Medicine Technology:
    (Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
    (Date:11/27/2015)... ... November 27, 2015 , ... The ... and prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, ... and helped advance the healthcare industry as a whole through their advocacy and ...
    (Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point Recovery, ... together on Thanksgiving Day to share the things that they are most grateful ... Point YouTube channel, patients displayed what they wrote on index cards, describing the ...
    (Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
    (Date:11/26/2015)... Viejo, CA (PRWEB) , ... November 26, 2015 ... ... users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This ... style options. These classically-influenced trailer titles work with any font, giving users limitless ...
    Breaking Medicine News(10 mins):